ERBB2 and breast carcinoma: A particular contrast with this predictive strategy is worth drawing with studies of post-therapy declines in PSA or circulating tumour cells, which similar to estrogen-receptor, HER2, and Oncotype DX in breast cancer, are tumour-derived predictors of therapeutic outcomes.